Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation
Status:
Completed
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
This study proposes to use quetiapine as an adjunct treatment to treatment as usual to
improve both substance use disorder (SUD) and mood symptoms in youth with SUD and severe mood
dysregulation (SMD). This is a randomized, double blind placebo controlled parallel design
study. Youth with symptoms of mood dysregulation and active substance use that meets criteria
for a SUD will be randomized to adjunct treatment with quetiapine or placebo. The
investigators hypothesize that treatment with quetiapine will lead to a reduction in
substance use, improvement in mood, and lead to greater engagement in outpatient treatment.
Phase:
Phase 4
Details
Lead Sponsor:
Boston Medical Center Massachusetts General Hospital